Deals this week: Ortho Clinical Diagnostics, Implandata Ophthalmic Products, SeaSpine Holdings

18 May 2018 (Last Updated May 18th, 2018 14:13)

Ortho Clinical Diagnostics Inc (Ortho) has signed an agreement with Sentinel Diagnostics Imaging Inc to provide a wide-range C-Reactive Protein assay named CRP Ultra (MP) Assay.

Ortho Clinical Diagnostics Inc (Ortho) has signed an agreement with Sentinel Diagnostics Imaging Inc to provide a wide-range C-Reactive Protein assay named CRP Ultra (MP) Assay.

The transaction is part of Ortho partners’ MicroTip Partnership Assays programme, under which the company works with other diagnostics companies to deliver innovative assays to laboratories and hospital networks that use its VITROS 4600 Chemistry System and VITROS 5600 Integrated System.

Ortho is an in-vitro diagnostics company serving the clinical laboratory and immunohematology communities, while Sentinel Diagnostics is a medical imaging analysis company.

Both the companies involved in the transaction are based in the US.

The acquisition will expand Ortho’s market reach for delivering innovative assays to its customers.

Implandata Ophthalmic Products GmbH (IOP) has raised funds through a Series C funding round led by Heidelberg Engineering GmbH, Occident Group AG, and NKB GmbH.

Existing investors KfW Group, High-Tech Grunderfonds Management GmbH (HTGF), and Peppermint Charite Beteiligungsfonds also participated in the funding round.

Based in Germany, Implandata is an ophthalmic medical device company.

The funds raised will be used towards the commercialisation of the company’s CE-marked EYEMATE system in Europe.

US-based medical technology company SeaSpine Holdings Corporation plans to raise $50m by issuing shares of its common stock.

“The funds raised will be used towards the commercialisation of the company’s CE-marked EYEMATE system in Europe.”

The company plans to use the funds towards product development, research and development expenditures and for other general corporate purposes.

US-based CHF Solutions Inc plans to raise $30m through a public offering of securities.

The funds are intended to be used for the commercialisation of Aquadex FlexFlow System, working capital, and other general corporate purposes.

CHF appointed Honigman Miller Schwartz and Cohn LLP as the legal advisor for the offering.

Vesper Medical Inc has raised $10.5m through a series A financing round from US-based venture capital firms New Enterprise Associates Inc and Quaker Partners Management LP.

Based in the US, Vesper is a developer of medical devices for minimally invasive peripheral vascular procedures.

The company plans to use the funds to complete the development and clinical testing of its Vesper Duo Venous Stent System.

ViewRay Inc plans to raise $150m through a public offering of securities.

The company will issue common stock, warrants, purchase contracts and units, as well as debt securities as part of the offering.

Based in the US, ViewRay is a manufacturer of radiation therapy systems.

The company intends to use the funds for working capital and other general corporate purposes.

Pulse Biosciences Inc is set to raise $37.51m by issuing 2.1 million shares of its common stock priced at $17.6 a share.

Based in the US, Pulse Biosciences is a medical device company that develops therapeutic tissue treatment platform based on Nano-Pulse Stimulation technology.